S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
Log in
NASDAQ:NVCR

NovoCure Stock Forecast, Price & News

$129.28
-3.97 (-2.98 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$117.49
Now: $129.28
$134.21
50-Day Range
$133.25
MA: $170.60
$190.17
52-Week Range
$53.40
Now: $129.28
$194.75
Volume1.21 million shs
Average Volume743,553 shs
Market Capitalization$13.24 billion
P/E Ratio680.46
Dividend YieldN/A
Beta1.29
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and NovoTTF-100L, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products that are in Phase 2 pilot and Phase 3 pivotal trials for brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and internationally. It has a clinical trial collaboration agreement with MSD to evaluate tumor treating fields together with KEYTRUDA, an anti-PD-1 therapy; and a strategic alliance with the NYU Grossman School of Medicine's Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey.
NovoCure logo

Headlines

Selling Before NVCR Stock Earnings Captured Quick Gain
February 26, 2021 |  finance.yahoo.com
NovoCure Has Broken Down on the Charts: What to Do Now
February 26, 2021 |  finance.yahoo.com
NovoCure (NVCR) Q4 2020 Earnings Call Transcript
February 26, 2021 |  finance.yahoo.com
Novocure Announces Addition to Its Board of Directors
February 8, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NVCR
CUSIPN/A
Phone44-0-15-3475-6700
Employees782
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$351.32 million
Book Value$2.20 per share

Profitability

Net Income$-7,230,000.00

Miscellaneous

Market Cap$13.24 billion
Next Earnings Date4/29/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.46 out of 5 stars

Medical Sector

537th out of 1,968 stocks

Surgical & Medical Instruments Industry

56th out of 169 stocks

Analyst Opinion: 1.2Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
$129.28
-3.97 (-2.98 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NVCR News and Ratings via Email

Sign-up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











NovoCure (NASDAQ:NVCR) Frequently Asked Questions

Is NovoCure a buy right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last year. There are currently 1 sell rating, 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NovoCure stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVCR, but not buy additional shares or sell existing shares.
View analyst ratings for NovoCure
or view top-rated stocks.

What stocks does MarketBeat like better than NovoCure?

Wall Street analysts have given NovoCure a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but NovoCure wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is NovoCure's next earnings date?

NovoCure is scheduled to release its next quarterly earnings announcement on Thursday, April 29th 2021.
View our earnings forecast for NovoCure
.

How were NovoCure's earnings last quarter?

NovoCure Limited (NASDAQ:NVCR) issued its earnings results on Thursday, February, 25th. The medical equipment provider reported $0.04 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.13 by $0.09. The medical equipment provider had revenue of $144 million for the quarter, compared to the consensus estimate of $143.49 million. NovoCure had a net margin of 4.26% and a trailing twelve-month return on equity of 7.40%. The business's revenue for the quarter was up 45.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.04 earnings per share.
View NovoCure's earnings history
.

How has NovoCure's stock been impacted by Coronavirus?

NovoCure's stock was trading at $67.38 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NVCR stock has increased by 91.9% and is now trading at $129.28.
View which stocks have been most impacted by COVID-19
.

What guidance has NovoCure issued on next quarter's earnings?

NovoCure issued an update on its FY 2020 Pre-Market earnings guidance on Monday, January, 11th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $494.4-494.4 million, compared to the consensus revenue estimate of $482.29 million.

What price target have analysts set for NVCR?

9 brokers have issued twelve-month price objectives for NovoCure's shares. Their forecasts range from $58.00 to $225.00. On average, they expect NovoCure's stock price to reach $129.13 in the next twelve months. This suggests that the stock has a possible downside of 0.1%.
View analysts' price targets for NovoCure
or view top-rated stocks among Wall Street analysts.

Who are NovoCure's key executives?

NovoCure's management team includes the following people:
  • Mr. William F. Doyle, Exec. Chairman (Age 59, Pay $1.66M)
  • Mr. Asaf Danziger, Pres, CEO & Director (Age 55, Pay $1.69M)
  • Mr. Wilhelmus C. M. Groenhuysen, Chief Operating Officer (Age 63, Pay $1.02M)
  • Mr. Pritesh Shah, Chief Commercial Officer (Age 43, Pay $725.6k)
  • Prof. Yoram Palti, Founder & CTO (Age 83)
  • Ms. Ashley Cordova, CFO & VP of Investor Relations
  • Mr. Todd C. Longsworth, Gen. Counsel (Age 46)
  • Dr. Ely Benaim, Chief Medical Officer (Age 60)
  • Mr. Uri Weinberg M.D., Ph.D., Chief Science Officer
  • Mr. Frank Leonard, Chief Devel. Officer

What is Asaf Danziger's approval rating as NovoCure's CEO?

17 employees have rated NovoCure CEO Asaf Danziger on Glassdoor.com. Asaf Danziger has an approval rating of 90% among NovoCure's employees.

Who are some of NovoCure's key competitors?

What other stocks do shareholders of NovoCure own?

What is NovoCure's stock symbol?

NovoCure trades on the NASDAQ under the ticker symbol "NVCR."

Who are NovoCure's major shareholders?

NovoCure's stock is owned by many different institutional and retail investors. Top institutional shareholders include FMR LLC (9.46%), Baillie Gifford & Co. (8.12%), BlackRock Inc. (5.69%), Morgan Stanley (1.33%), Price T Rowe Associates Inc. MD (1.22%) and Wells Fargo & Company MN (1.12%). Company insiders that own NovoCure stock include Asaf Danziger, Ashley Cordova, Charles G Phillips III, Ely Benaim, Gabriel Leung, Jeryl L Hilleman, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle.
View institutional ownership trends for NovoCure
.

Which institutional investors are selling NovoCure stock?

NVCR stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, FMR LLC, Rhenman & Partners Asset Management AB, BlackRock Inc., C WorldWide Group Holding A S, Phoenix Holdings Ltd., Nicholas Investment Partners LP, and Peregrine Capital Management LLC. Company insiders that have sold NovoCure company stock in the last year include Asaf Danziger, Ashley Cordova, Ely Benaim, Gabriel Leung, Jeryl L Hilleman, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen, and William F Doyle.
View insider buying and selling activity for NovoCure
or view top insider-selling stocks.

Which institutional investors are buying NovoCure stock?

NVCR stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Victory Capital Management Inc., First Trust Advisors LP, Cookson Peirce & Co. Inc., Baillie Gifford & Co., Nuveen Asset Management LLC, Swiss National Bank, and UBS Asset Management Americas Inc..
View insider buying and selling activity for NovoCure
or or view top insider-buying stocks.

How do I buy shares of NovoCure?

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NovoCure's stock price today?

One share of NVCR stock can currently be purchased for approximately $129.28.

How much money does NovoCure make?

NovoCure has a market capitalization of $13.24 billion and generates $351.32 million in revenue each year. The medical equipment provider earns $-7,230,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis.

How many employees does NovoCure have?

NovoCure employs 782 workers across the globe.

What is NovoCure's official website?

The official website for NovoCure is www.novocure.com.

Where are NovoCure's headquarters?

NovoCure is headquartered at NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF.

How can I contact NovoCure?

NovoCure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]


This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.